MapLight Therapeutics (MPLT) stock: insider trades, news & valuation
Health Care · Strong buying
Close · Oct 9, 2026
$8.83
-3.5% on the day
-51.9% over 12 months
52-week range $8.83 – $39.80
Share price and insider trades
MPLT closeInsider buyInsider sale
Bought, 12 months$175M
Sold, 12 months$29.2M
Insiders buying5
Insiders selling8
MapLight Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 5 insiders bought $175M and 8 sold $29.2M of MPLT stock on the open market.
Get emailed when insiders cluster-buy stocks like MPLT
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
MPLT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $65.5M | 6 | $11.6M | 46 |
| Q2 2026 | — | 0 | $16.2M | 80 |
| Q1 2026 | $694K | 4 | $1.4M | 13 |
| Q4 2025 | $109M | 2 | — | 0 |
Valuation, profit and volume
P/E (trailing)n/aSector median 24.7
Market value$491MBiotechnology
Profit margin0.0%Revenue growth —
Volume vs. 50-day0.4×Last 5 sessions
Insiders' paper profit−$68.5MOn all tracked purchases -39.1%
Summary
Over the past 12 months, 5 MapLight Therapeutics, Inc. insiders reported open-market purchases totaling $175M, while 8 insiders reported sales totaling $29.2M. Among insiders with enough purchase history to measure, Novo Holdings A/S (10% Owner) has the highest Insider Score at 49. 88 of 139 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
MPLT stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 18SEC | Kristopher HansonGeneral Counsel | Sell Plan | 16,509137,044 held (−11%) | $11.67 | $193K | -24.3% | — |
| Aug 18SEC | Catalyst4, Inc.10% Owner | Buy | 4,400,00025,306,689 held (+21%) | $11.38 | $50.1M | -22.4% | — |
| Aug 4SEC | James Woodruff LillieChief Scientific Officer | Sell Plan | 22,082202,380 held (−10%) | $12.54 | $277K | -29.6% | — |
| Jul 30SEC | Catalyst4, Inc.10% Owner | Buy | 1,000,00020,906,689 held (+5%) | $13.00 | $13.0M | -32.1% | — |
| Jul 30SEC | Catalyst4, Inc.10% Owner | Buy | 141,08819,838,552 held (+1%) | $10.74 | $1.5M | -17.8% | — |
| Jul 30SEC | Catalyst4, Inc.10% Owner | Buy | 65,13719,903,689 held (+0%) | $11.69 | $761K | -24.5% | — |
| Jul 30SEC | Catalyst4, Inc.10% Owner | Buy | 3,00019,906,689 held (+0%) | $12.63 | $38K | -30.1% | — |
| Jul 28SEC | Troy CoxDirector | Buy | 15,620new position | $9.52 | $149K | -7.2% | — |
| Jul 20SEC | Jonathan GillisCFO | Sell Plan | 16,969145,140 held (−10%) | $37.61 | $638K | -76.5% | — |
| Jul 20SEC | Anatol KreitzerChief Discovery Officer | Sell Plan | 14,140175,106 held (−7%) | $37.70 | $533K | -76.6% | — |
| Jul 20SEC | Anatol KreitzerChief Discovery Officer | Sell Plan | 7,464193,671 held (−4%) | $36.66 | $274K | -75.9% | — |
| Jul 20SEC | Jonathan GillisCFO | Sell Plan | 6,979164,185 held (−4%) | $36.66 | $256K | -75.9% | — |
| Jul 20SEC | Anatol KreitzerChief Discovery Officer | Sell Plan | 5,545205,645 held (−3%) | $36.13 | $200K | -75.6% | — |
| Jul 20SEC | Jonathan GillisCFO | Sell Plan | 5,356175,863 held (−3%) | $36.13 | $194K | -75.6% | — |
| Jul 20SEC | Jonathan GillisCFO | Sell Plan | 4,699171,164 held (−3%) | $36.94 | $174K | -76.1% | — |
| Jul 20SEC | Anatol KreitzerChief Discovery Officer | Sell Plan | 4,510201,135 held (−2%) | $36.94 | $167K | -76.1% | — |
| Jul 20SEC | Anatol KreitzerChief Discovery Officer | Sell Plan | 2,833189,246 held (−1%) | $37.05 | $105K | -76.2% | — |
| Jul 20SEC | Anatol KreitzerChief Discovery Officer | Sell Plan | 1,592192,079 held (−1%) | $37.44 | $60K | -76.4% | — |
| Jul 20SEC | Jonathan GillisCFO | Sell Plan | 1,476162,709 held (−1%) | $37.44 | $55K | -76.4% | — |
| Jul 20SEC | Jonathan GillisCFO | Sell Plan | 900144,240 held (−1%) | $38.17 | $34K | -76.9% | — |
| Jul 20SEC | Jonathan GillisCFO | Sell Plan | 600162,109 held (−0%) | $36.51 | $22K | -75.8% | — |
| Jul 20SEC | Anatol KreitzerChief Discovery Officer | Sell Plan | 200174,906 held (−0%) | $38.39 | $8K | -77.0% | — |
| Jul 17SEC | Christopher A. KroegerCEO | Sell | 42,7381,332,406 held (−3%) | $36.99 | $1.6M | -76.1% | — |
| Jul 17SEC | Christopher A. KroegerCEO | Sell | 40,8991,291,417 held (−3%) | $36.46 | $1.5M | -75.8% | — |
| Jul 17SEC | Christopher A. KroegerCEO | Sell | 28,0911,263,326 held (−2%) | $37.26 | $1.0M | -76.3% | — |
| Jul 17SEC | Christopher A. KroegerCEO | Sell | 18,9501,375,144 held (−1%) | $36.00 | $682K | -75.5% | — |
| Jul 17SEC | Christopher A. KroegerCEO | Sell | 16,7791,246,455 held (−1%) | $37.90 | $636K | -76.7% | — |
| Jul 17SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 9,163308,441 held (−3%) | $36.46 | $334K | -75.8% | — |
| Jul 17SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 8,972317,622 held (−3%) | $36.99 | $332K | -76.1% | — |
| Jul 17SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 7,845331,059 held (−2%) | $37.04 | $291K | -76.2% | — |
| Jul 17SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 7,155338,904 held (−2%) | $36.16 | $259K | -75.6% | — |
| Jul 17SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 5,865302,576 held (−2%) | $37.26 | $219K | -76.3% | — |
| Jul 17SEC | James Woodruff LillieChief Scientific Officer | Sell | 5,393235,098 held (−2%) | $36.99 | $199K | -76.1% | — |
| Jul 17SEC | Kristopher HansonGeneral Counsel | Sell | 5,103155,081 held (−3%) | $36.99 | $189K | -76.1% | — |
| Jul 17SEC | James Woodruff LillieChief Scientific Officer | Sell | 5,009230,077 held (−2%) | $36.45 | $183K | -75.8% | — |
| Jul 17SEC | Kristopher HansonGeneral Counsel | Sell | 4,776150,295 held (−3%) | $36.45 | $174K | -75.8% | — |
| Jul 17SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 4,465326,594 held (−1%) | $36.00 | $161K | -75.5% | — |
| Jul 17SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 3,656298,901 held (−1%) | $37.90 | $139K | -76.7% | — |
| Jul 17SEC | James Woodruff LillieChief Scientific Officer | Sell | 3,526226,551 held (−2%) | $37.26 | $131K | -76.3% | — |
| Jul 17SEC | Kristopher HansonGeneral Counsel | Sell | 3,331146,964 held (−2%) | $37.26 | $124K | -76.3% | — |
| Jul 17SEC | James Woodruff LillieChief Scientific Officer | Sell | 2,238240,491 held (−1%) | $36.00 | $81K | -75.5% | — |
| Jul 17SEC | James Woodruff LillieChief Scientific Officer | Sell | 2,077224,462 held (−1%) | $37.90 | $79K | -76.7% | — |
| Jul 17SEC | Kristopher HansonGeneral Counsel | Sell | 2,147160,184 held (−1%) | $36.00 | $77K | -75.5% | — |
| Jul 17SEC | Kristopher HansonGeneral Counsel | Sell | 1,130145,823 held (−1%) | $37.90 | $43K | -76.7% | — |
| Jul 17SEC | Christopher A. KroegerCEO | Sell | 921,263,234 held (−0%) | $37.96 | $3K | -76.7% | — |
| Jul 17SEC | Christopher A. KroegerCEO | Sell | 901,332,316 held (−0%) | $37.54 | $3K | -76.5% | — |
| Jul 17SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 19302,557 held (−0%) | $37.96 | $721 | -76.7% | — |
| Jul 17SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 18317,604 held (−0%) | $37.54 | $676 | -76.5% | — |
| Jul 17SEC | James Woodruff LillieChief Scientific Officer | Sell | 12226,539 held (−0%) | $37.96 | $456 | -76.7% | — |
| Jul 17SEC | James Woodruff LillieChief Scientific Officer | Sell | 12235,086 held (−0%) | $37.54 | $450 | -76.5% | — |
| Jul 17SEC | Kristopher HansonGeneral Counsel | Sell | 11146,953 held (−0%) | $37.96 | $418 | -76.7% | — |
| Jul 17SEC | Kristopher HansonGeneral Counsel | Sell | 10155,071 held (−0%) | $37.54 | $375 | -76.5% | — |
| May 18SEC | Christopher A. KroegerCEO | Sell Plan | 118,0371,394,292 held (−8%) | $27.19 | $3.2M | -67.5% | — |
| May 18SEC | Christopher A. KroegerCEO | Sell Plan | 1981,394,094 held (−0%) | $28.15 | $6K | -68.6% | — |
| May 11SEC | Christopher A. KroegerCEO | Sell Plan | 29,6241,531,096 held (−2%) | $27.48 | $814K | -67.9% | — |
| May 11SEC | Christopher A. KroegerCEO | Sell Plan | 14,8801,565,940 held (−1%) | $28.47 | $424K | -69.0% | — |
| May 11SEC | Kristopher HansonGeneral Counsel | Sell Plan | 6,979168,139 held (−4%) | $30.04 | $210K | -70.6% | — |
| May 11SEC | Christopher A. KroegerCEO | Sell Plan | 6,8711,518,219 held (−0%) | $30.04 | $206K | -70.6% | — |
| May 11SEC | Christopher A. KroegerCEO | Sell Plan | 5,8901,512,329 held (−0%) | $30.56 | $180K | -71.1% | — |
| May 11SEC | Kristopher HansonGeneral Counsel | Sell Plan | 5,808162,331 held (−3%) | $30.56 | $177K | -71.1% | — |
| May 11SEC | Christopher A. KroegerCEO | Sell Plan | 5,2201,560,720 held (−0%) | $29.15 | $152K | -69.7% | — |
| May 11SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 4,321346,176 held (−1%) | $28.52 | $123K | -69.0% | — |
| May 11SEC | Christopher A. KroegerCEO | Sell Plan | 3,2051,526,309 held (−0%) | $29.20 | $94K | -69.8% | — |
| May 11SEC | Christopher A. KroegerCEO | Sell Plan | 1,5821,529,514 held (−0%) | $28.56 | $45K | -69.1% | — |
| May 11SEC | Christopher A. KroegerCEO | Sell Plan | 8771,525,090 held (−0%) | $28.70 | $25K | -69.2% | — |
| May 11SEC | Kristopher HansonGeneral Counsel | Sell Plan | 846175,118 held (−0%) | $28.70 | $24K | -69.2% | — |
| May 11SEC | James Woodruff LillieChief Scientific Officer | Sell Plan | 721242,729 held (−0%) | $28.28 | $20K | -68.8% | — |
| May 11SEC | Christopher A. KroegerCEO | Sell Plan | 3421,525,967 held (−0%) | $27.57 | $9K | -68.0% | — |
| May 11SEC | Kristopher HansonGeneral Counsel | Sell Plan | 284175,964 held (−0%) | $27.61 | $8K | -68.0% | — |
| May 11SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 117346,059 held (−0%) | $29.10 | $3K | -69.7% | — |
| May 6SEC | James Woodruff LillieChief Scientific Officer | Sell Plan | 16,421243,450 held (−6%) | $29.13 | $478K | -69.7% | — |
| May 6SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 15,900350,497 held (−4%) | $29.13 | $463K | -69.7% | — |
| May 6SEC | Christopher A. KroegerCEO | Sell Plan | 15,6031,580,820 held (−1%) | $29.13 | $455K | -69.7% | — |
| May 6SEC | James Woodruff LillieChief Scientific Officer | Sell Plan | 10,132269,224 held (−4%) | $28.12 | $285K | -68.6% | — |
| May 6SEC | Vishwas SetiaCFO | Sell Plan | 9,935367,788 held (−3%) | $28.12 | $279K | -68.6% | — |
| May 6SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 9,645375,480 held (−3%) | $28.12 | $271K | -68.6% | — |
| May 6SEC | Christopher A. KroegerCEO | Sell Plan | 9,5441,605,449 held (−1%) | $28.12 | $268K | -68.6% | — |
| May 6SEC | James Woodruff LillieChief Scientific Officer | Sell Plan | 9,250285,907 held (−3%) | $27.50 | $254K | -67.9% | — |
| May 6SEC | Vishwas SetiaCFO | Sell Plan | 8,989378,835 held (−2%) | $28.28 | $254K | -68.8% | — |
| May 6SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 9,180391,597 held (−2%) | $27.50 | $252K | -67.9% | — |
| May 6SEC | Christopher A. KroegerCEO | Sell Plan | 9,1361,621,428 held (−1%) | $27.50 | $251K | -67.9% | — |
| May 6SEC | Kristopher HansonGeneral Counsel | Sell Plan | 9,030181,135 held (−5%) | $27.50 | $248K | -67.9% | — |
| May 6SEC | Vishwas SetiaCFO | Sell Plan | 8,496358,324 held (−2%) | $28.04 | $238K | -68.5% | — |
| May 6SEC | James Woodruff LillieChief Scientific Officer | Sell Plan | 8,390259,871 held (−3%) | $28.04 | $235K | -68.5% | — |
| May 6SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 8,152366,397 held (−2%) | $28.04 | $229K | -68.5% | — |
| May 6SEC | Christopher A. KroegerCEO | Sell Plan | 8,0981,596,423 held (−1%) | $28.04 | $227K | -68.5% | — |
| May 6SEC | James Woodruff LillieChief Scientific Officer | Sell Plan | 5,526280,381 held (−2%) | $28.37 | $157K | -68.9% | — |
| May 6SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 5,460386,137 held (−1%) | $28.37 | $155K | -68.9% | — |
| May 6SEC | Christopher A. KroegerCEO | Sell Plan | 5,4271,616,001 held (−0%) | $28.37 | $154K | -68.9% | — |
| May 6SEC | Vishwas SetiaCFO | Sell Plan | 4,803387,824 held (−1%) | $27.36 | $131K | -67.7% | — |
| May 6SEC | Kristopher HansonGeneral Counsel | Sell Plan | 3,908177,227 held (−2%) | $28.29 | $111K | -68.8% | — |
| May 6SEC | Vishwas SetiaCFO | Sell Plan | 2,068356,256 held (−1%) | $29.07 | $60K | -69.6% | — |
| May 6SEC | Vishwas SetiaCFO | Sell Plan | 968366,820 held (−0%) | $29.00 | $28K | -69.6% | — |
| May 6SEC | James Woodruff LillieChief Scientific Officer | Sell Plan | 963268,261 held (−0%) | $29.00 | $28K | -69.6% | — |
| May 6SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 931374,549 held (−0%) | $29.00 | $27K | -69.6% | — |
| May 6SEC | Christopher A. KroegerCEO | Sell Plan | 9281,604,521 held (−0%) | $29.00 | $27K | -69.6% | — |
| May 6SEC | Vishwas SetiaCFO | Sell Plan | 787377,723 held (−0%) | $30.12 | $24K | -70.7% | — |
| May 6SEC | James Woodruff LillieChief Scientific Officer | Sell Plan | 705279,356 held (−0%) | $30.08 | $21K | -70.6% | — |
| May 6SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 700385,125 held (−0%) | $30.08 | $21K | -70.6% | — |
| May 6SEC | Christopher A. KroegerCEO | Sell Plan | 6971,614,993 held (−0%) | $30.08 | $21K | -70.6% | — |
| May 6SEC | Kristopher HansonGeneral Counsel | Sell Plan | 683176,248 held (−0%) | $30.08 | $21K | -70.6% | — |
| May 6SEC | Vishwas SetiaCFO | Sell Plan | 325378,510 held (−0%) | $29.56 | $10K | -70.1% | — |
| May 6SEC | James Woodruff LillieChief Scientific Officer | Sell Plan | 320280,061 held (−0%) | $29.56 | $9K | -70.1% | — |
| May 6SEC | Erin Pennock FoffChief Medical Officer | Sell Plan | 312385,825 held (−0%) | $29.56 | $9K | -70.1% | — |
| May 6SEC | Christopher A. KroegerCEO | Sell Plan | 3111,615,690 held (−0%) | $29.56 | $9K | -70.1% | — |
| May 6SEC | Kristopher HansonGeneral Counsel | Sell Plan | 296176,931 held (−0%) | $29.56 | $9K | -70.1% | — |
| Apr 29SEC | Jonathan GillisCaao And Pao | Sell Plan | 29,623213,517 held (−12%) | $29.60 | $877K | -70.2% | — |
| Apr 29SEC | Anatol KreitzerChief Discovery Officer | Sell Plan | 29,255219,011 held (−12%) | $29.63 | $867K | -70.2% | — |
| Apr 29SEC | Jonathan GillisCaao And Pao | Sell Plan | 17,235181,919 held (−9%) | $30.33 | $523K | -70.9% | — |
| Apr 29SEC | Jonathan GillisCaao And Pao | Sell Plan | 14,363199,154 held (−7%) | $30.46 | $437K | -71.0% | — |
| Apr 29SEC | Anatol KreitzerChief Discovery Officer | Sell Plan | 8,346248,266 held (−3%) | $28.96 | $242K | -69.5% | — |
| Apr 29SEC | Anatol KreitzerChief Discovery Officer | Sell Plan | 7,821211,190 held (−4%) | $30.50 | $239K | -71.0% | — |
| Apr 29SEC | Jonathan GillisCaao And Pao | Sell Plan | 7,914243,140 held (−3%) | $28.94 | $229K | -69.5% | — |
| Apr 29SEC | Jonathan GillisCaao And Pao | Sell Plan | 700181,219 held (−0%) | $30.83 | $22K | -71.4% | — |
| Apr 17SEC | Christopher A. KroegerCEO | Sell | 9,1351,640,616 held (−1%) | $26.93 | $246K | -67.2% | — |
| Apr 17SEC | Robert C. MalenkaDirector | Sell Plan | 8,593316,466 held (−3%) | $26.90 | $231K | -67.2% | — |
| Apr 17SEC | Christopher A. KroegerCEO | Sell | 7,5751,630,564 held (−0%) | $27.49 | $208K | -67.9% | — |
| Apr 17SEC | Jonathan GillisCaao And Pao | Sell | 3,590251,054 held (−1%) | $26.61 | $96K | -66.8% | — |
| Apr 17SEC | Anatol KreitzerChief Discovery Officer | Sell | 3,316256,612 held (−1%) | $26.61 | $88K | -66.8% | — |
| Apr 17SEC | Vishwas SetiaCFO | Sell | 2,806392,743 held (−1%) | $26.87 | $75K | -67.1% | — |
| Apr 17SEC | Christopher A. KroegerCEO | Sell | 2,4771,638,139 held (−0%) | $27.01 | $67K | -67.3% | — |
| Apr 17SEC | James Woodruff LillieChief Scientific Officer | Sell | 2,097295,157 held (−1%) | $27.49 | $58K | -67.9% | — |
| Apr 17SEC | Erin Pennock FoffChief Medical Officer | Sell | 2,044401,946 held (−1%) | $26.84 | $55K | -67.1% | — |
| Apr 17SEC | James Woodruff LillieChief Scientific Officer | Sell | 1,730297,940 held (−1%) | $26.82 | $46K | -67.1% | — |
| Apr 17SEC | Kristopher HansonGeneral Counsel | Sell | 1,529190,463 held (−1%) | $26.80 | $41K | -67.1% | — |
| Apr 17SEC | Erin Pennock FoffChief Medical Officer | Sell | 881400,777 held (−0%) | $27.49 | $24K | -67.9% | — |
| Apr 17SEC | James Woodruff LillieChief Scientific Officer | Sell | 686297,254 held (−0%) | $27.01 | $19K | -67.3% | — |
| Apr 17SEC | Erin Pennock FoffChief Medical Officer | Sell | 288401,658 held (−0%) | $27.01 | $8K | -67.3% | — |
| Apr 17SEC | Kristopher HansonGeneral Counsel | Sell | 225190,165 held (−0%) | $27.49 | $6K | -67.9% | — |
| Apr 17SEC | Vishwas SetiaCFO | Sell | 87392,627 held (−0%) | $27.49 | $2K | -67.9% | — |
| Apr 17SEC | Kristopher HansonGeneral Counsel | Sell | 73190,390 held (−0%) | $27.01 | $2K | -67.3% | — |
| Apr 17SEC | Vishwas SetiaCFO | Sell | 29392,714 held (−0%) | $27.01 | $783 | -67.3% | — |
| Feb 24SEC | Robert C. MalenkaDirector | Sell | 10,788326,271 held (−3%) | $18.39 | $198K | -52.0% | — |
| Feb 24SEC | Robert C. MalenkaDirector | Sell | 2,195337,059 held (−1%) | $18.03 | $40K | -51.0% | — |
| Feb 24SEC | Robert C. MalenkaDirector | Sell | 736325,059 held (−0%) | $18.15 | $13K | -51.3% | — |
| Feb 24SEC | Robert C. MalenkaDirector | Sell | 476325,795 held (−0%) | $19.06 | $9K | -53.7% | — |
| Feb 20SEC | George PavlovDirector | Buy | 10,658new position | $17.48 | $186K | -49.5% | — |
| Feb 20SEC | George PavlovDirector | Buy | 9,92025,000 held (+66%) | $17.86 | $177K | -50.6% | — |
| Feb 20SEC | George PavlovDirector | Buy | 4,42215,080 held (+41%) | $17.57 | $78K | -49.7% | — |
| Feb 18SEC | Robert C. MalenkaDirector | Sell | 12,116339,254 held (−3%) | $18.21 | $221K | -51.5% | — |
| Feb 12SEC | Timothy John GarnettDirector | Buy | 14,124new position | $17.89 | $253K | -50.6% | — |
| Feb 12SEC | Robert C. MalenkaDirector | Sell | 6,622351,611 held (−2%) | $18.12 | $120K | -51.3% | — |
| Feb 12SEC | Robert C. MalenkaDirector | Sell | 241351,370 held (−0%) | $18.00 | $4K | -50.9% | — |
| Feb 4SEC | Robert C. MalenkaDirector | Sell | 7,039358,234 held (−2%) | $18.02 | $127K | -51.0% | — |
| Feb 4SEC | Robert C. MalenkaDirector | Sell | 1358,233 held (−0%) | $18.00 | $18 | -50.9% | — |
| Jan 30SEC | Robert C. MalenkaDirector | Sell | 21,262371,885 held (−5%) | $18.55 | $394K | -52.4% | — |
| Jan 30SEC | Robert C. MalenkaDirector | Sell | 6,612365,273 held (−2%) | $18.11 | $120K | -51.2% | — |
| Jan 30SEC | Robert C. MalenkaDirector | Sell | 5,860393,811 held (−1%) | $18.61 | $109K | -52.6% | — |
| Jan 30SEC | Robert C. MalenkaDirector | Sell | 664393,147 held (−0%) | $19.05 | $13K | -53.6% | — |
| Oct 30SEC | Novo Holdings A/S10% Owner | Buy | 952,9413,686,622 held (+35%) | $17.00 | $16.2M | -48.1% | 49 |
| Oct 29SEC | Catalyst4, Inc.10% Owner | Buy | 5,441,17619,697,464 held (+38%) | $17.00 | $92.5M | -48.1% | — |
Insiders at MapLight Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Catalyst4, Inc.10% Owner | $158M | — | Aug 18, 2026 | — |
| Novo Holdings A/S10% Owner | $16.2M | — | Oct 30, 2025 | 49 |
| Christopher A. KroegerCEO | — | $12.5M | Jul 17, 2026 | — |
| Jonathan GillisCFO | — | $3.6M | Jul 20, 2026 | — |
| Erin Pennock FoffChief Medical Officer | — | $3.4M | Jul 17, 2026 | — |
| Anatol KreitzerChief Discovery Officer | — | $2.8M | Jul 20, 2026 | — |
| James Woodruff LillieChief Scientific Officer | — | $2.6M | Aug 4, 2026 | — |
| Kristopher HansonGeneral Counsel | — | $1.7M | Sep 18, 2026 | — |
| Robert C. MalenkaDirector | — | $1.6M | Apr 17, 2026 | — |
| George PavlovDirector | $441K | — | Feb 20, 2026 | — |
| Vishwas SetiaCFO | — | $1.1M | May 6, 2026 | — |
| Timothy John GarnettDirector | $253K | — | Feb 12, 2026 | — |
| Troy CoxDirector | $149K | — | Jul 28, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
MPLT stock: common questions
Are MapLight Therapeutics, Inc. insiders buying MPLT stock?
In the past 12 months, 5 insiders reported open-market purchases of MPLT worth $175M. The latest was 10% Owner Catalyst4, Inc. bought $50.1M of MPLT at $11.38 — raises the stake by 21%.
Are MapLight Therapeutics, Inc. insiders selling MPLT stock?
8 insiders reported sales worth $29.2M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is MPLT's 52-week range?
Over the past year MPLT has traded between $8.83 and $39.80. It last closed at $8.83 on Oct 9, 2026.